ANI Pharmaceuticals Inc
ANIP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.55B
Close$
$-54.62
176.8% downside
Current Fair Value
176.8% downsideOvervalued by 176.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.55 Billion |
|---|---|
| Enterprise Value | $1.43 Billion |
| Earnings per Share | $3.5 |
| Beta | 0.47 |
| Outstanding Shares | 21,212,000 |
Return
| Return on Equity | 18.73% |
|---|---|
| Return on Assets | 7.61% |
| Return on Invested Capital | 14.60% |
Valuation & Multiples
| P/E Ratio | 13.01 |
|---|---|
| PEG | 40.6 |
| Price to Sales | 1.45 |
| Price to Book Ratio | 2.37 |
| Enterprise Value to Revenue | 1.38 |
| Enterprise Value to EBIT | 7.93 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.48 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 6, 2026
EPS Estimate
$2.18
Consensus analyst estimateRevenue Estimate
$280.26 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 26, 2027
EPS Estimate
$2.58
Consensus analyst estimateRevenue Estimate
$303.61 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 2404.44% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.96%▼ 89.78% |
|---|---|
| Total Invested | $306.86M▼ 84.03% |
| Investors Holding | 112▼ 203.00% |
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...